Using data of the prospective AMLCG 1999 trial, we performed a matched pairs analysis to evaluate outcome in patients (pts) with AML according to postremission allo-SCT or randomly allocated autologous SCT or maintenance chemotherapy. As of 07/2007, 2547 pts accrued to the trial were evaluable. 135 pt pairs in CR1 were identified who matched for the following criteria:
AML type (de novo AML, s-AML, t-AML, MDS);
cytogenetic risk group [unfavorable (UNF-CG), intermediate (INT-CG), and favorable with the exclusion of t(15;17)];
age (± 5 years); and
time in CR1 to account for the time to transplant in allo-SCT pts.
30 pt pairs had an UNF-CG, 97 pairs INT-CG, and 8 pairs had favorable cytogenetics. Median pt age was 45 years (range: 16–63). In the control cohort, 86 pts were assigned to cyclic maintenance chemotherapy and 49 to autologous SCT (see
Disclosure: No relevant conflicts of interest to declare.